...
首页> 外文期刊>Primary care companion to the journal of clinical psychiatry >Effectiveness of Antipsychotic Drugs for 24-Month Maintenance Treatment in First-Episode Schizophrenia: Evidence From a Community-Based a€?Real-Worlda€? Study
【24h】

Effectiveness of Antipsychotic Drugs for 24-Month Maintenance Treatment in First-Episode Schizophrenia: Evidence From a Community-Based a€?Real-Worlda€? Study

机译:抗精神病药对首发精神分裂症患者24个月维持治疗的有效性:来自基于社区的“真实世界”的证据研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: Maintenance treatment of schizophrenia with antipsychotic medications has become a standard for the prevention of psychotic relapse. However, little is known about the effectiveness of antipsychotic drugs for maintenance treatment in “real-world” populations with schizophrenia. We carried out a prospective study to assess the effectiveness of the most frequently prescribed antipsychotic drugs in the maintenance treatment of schizophrenia from 2 community settings. Methods: This study was conducted from October 2011 to December 2014. All participants were diagnosed with schizophrenia according to DSM-IV, were treated with an antipsychotic monotherapy, and were registered in a case management program with monthly monitoring for 24 months. The primary outcome measure, Positive and Negative Syndrome Scale (PANSS), and the Clinical Global Impressions-Severity of Illness (CGI-S) and -Improvement (CGI-I) scales were used to evaluate symptom severity and treatment response. The Personal and Social Performance scale (PSP) was used to evaluate the patients’ social functioning. The Medication Adherence Rating Scale (MARS) was used to assess medication adherence behavior. On the basis of antipsychotic used at baseline, patients were clustered into 7 groups: aripiprazole (n = 21), clozapine (n = 84), chlorpromazine (n = 61), olanzapine (n = 34), perphenazine (n = 21), quetiapine (n = 27), and risperidone (n = 99). Results: Of the 347 patients enrolled in the study, 312 completed the 24-month follow-up. There were no significant differences among the treatment groups in the PANSS total and subscale scores or the CGI-S and CGI-I scores over 24 months (all P values .05). There were also no significant differences in interactions between PSP scores and antipsychotic drugs (P = .17). The remission rates increased as the follow-time lapsed in all groups, but no significant difference was observed in remission rates at each time point among the 7 groups (P values .05). At the endpoint, MARS total scores were over 6, but did not significantly differ among the studied drugs (P = .24). Conclusions: These findings suggest that antipsychotic drugs can achieve equivalent effectiveness in maintenance treatment of first-episode schizophrenia through a well-organized case management program and family participation.
机译:目的:用抗精神病药物维持治疗精神分裂症已成为预防精神病复发的标准。但是,对于精神分裂症的“现实世界”人群中抗精神病药物用于维持治疗的有效性知之甚少。我们进行了一项前瞻性研究,以评估最常用的抗精神病药在2个社区环境中对精神分裂症维持治疗的有效性。方法:该研究于2011年10月至2014年12月进行。所有参与者均根据DSM-IV诊断为精神分裂症,接受了抗精神病药物单一疗法治疗,并登记在病例管理程序中,每月监测24个月。主要结局指标为阳性和阴性综合征量表(PANSS),以及临床总体印象-疾病严重程度(CGI-S)和-改善(CGI-I)量表用于评估症状的严重程度和治疗反应。个人和社会绩效量表(PSP)用于评估患者的社会功能。药物依从性评定量表(MARS)用于评估药物依从性。根据基线使用的抗精神病药,将患者分为7组:阿立哌唑(n = 21),氯氮平(n = 84),氯丙嗪(n = 61),奥氮平(n = 34),奋乃静(n = 21) ,喹硫平(n = 27)和利培酮(n = 99)。结果:纳入研究的347位患者中,有312位完成了24个月的随访。各治疗组之间在24个月内的PANSS总分和分量表得分或CGI-S和CGI-I得分之间无显着差异(所有P值均大于0.05)。 PSP评分与抗精神病药物之间的相互作用也没有显着差异(P = .17)。所有组的缓解率均随随访时间的增加而增加,但在7个组中,每个时间点的缓解率均未观察到显着差异(P值> 0.05)。在终点,MARS总分超过6,但在所研究的药物之间没有显着差异(P = 0.24)。结论:这些发现表明,抗精神病药可以通过精心组织的病例管理计划和家庭参与,在维持首发精神分裂症的维持治疗中达到同等效力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号